黑色素瘤抗原-A1 -A3的表达与喉癌临床特征相关性的研究  

Correlation between expression of MAGE-A1 and MAGE-A3 and clinical characteristics of laryngeal carcinoma

作　　者：程艳[1] 王斌全[2] 张春明[2] 刘海燕[1] 

机构地区：[1]山西医科大学第一医院核医学科,太原030001 [2]山西医科大学第一医院耳鼻喉科,太原030001

出　　处：《中国药物与临床》2015年第10期1381-1384,共4页Chinese Remedies & Clinics

基　　金：国家自然科学基金(30772405);山西医科大学校科技创新基金(01201319)

摘　　要：目的了解不同分期喉癌患者手术前后的肿瘤-睾丸抗原(CTA)家族中的黑色素瘤抗原-A1(MAGE-A1)和黑色素瘤抗原-A3(MAGE-A3)的血清学浓度变化情况,筛选喉癌诊断的CTA血清标志物。方法采用酶联免疫吸附试验(ELISA)法检测25例喉癌患者手术前、手术后血清中的MAGE-A1和MAGE-A3水平,并进一步检测46例喉癌患者手术前组、33例喉癌患者手术后组和20名健康人血清中的5种CTA。结果 ELISA法检测25例喉癌患者手术前、手术后血清中MAGE-A1和MAGE-A3浓度差异有统计学意义(P<0.05)。在46例喉癌患者手术前组、33例喉癌患者手术后组和20名健康人中,MAGE-A1和MAGE-A3手术前组和健康人组血清的浓度差异有统计学意义(P<0.05)。结论 MAGE-A1和MAGE-A3有可能成为喉癌诊断和预测复发的CTA血清标志物。Objective To investigate the serological concentration changes of melanoma antigen-A1 （MAGE-A1） and melanoma antigen-A3 （MAGE-A3） of the cancer-testis antigen （CTA） family in patients with laryngeal carci-noma at different stages before and after the operation, and to screen the CTA serum markers of the laryngeal carcino-ma diagnosis. Methods Enzyme-linked immunosorbent assay （ELISA） was used to determine the serum MAGE-A1 and MAGE-A3 in 25 patients with laryngeal cell carcinoma （LCC） before and after the operation. Then, 5 CTA serum markers were determined in the preoperative LCC group （n=46）, postoperative LCC group （n=33） and normal group （n=20）. Results ELISA showed that there were significant differences between preoperative and postoperative serum MAGE-A1 and MAGE-A3 concentration in 25 LCC patients （P〈0.05）. Among the preoperative LCC group （n=46）, postoperative LCC group （n=33） and normal group （n=20）, there were significant differences in serum MAGE-A1 and MAGE-A3 concentration between the preoperative groups and normal group （P〈0.05）. Conclusion MAGE-A1 and MAGE-A3 may become CTA serum markers for the LCC diagnosis and prediction of LSCC recurrence.

关 键 词：喉肿瘤 黑色素瘤特异性抗原 肿瘤-睾丸抗原 血清标志物 

分 类 号：R739.65[医药卫生—肿瘤]